Highbridge Capital Management’s Repros Therapeutics Inc. RPRX Stock Holding History

Highbridge Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-16,188	Closed	-$116K	–	2083
2015 Q2	$116K	Sell	16,188 -33,742	-68%	-$263K	﹤0.01%	1331
2015 Q1	$429K	Sell	49,930 -104,410	-68%	-$934K	0.01%	1011
2014 Q4	$1.54M	Buy	154,340 +91,842	+147%	+$783K	0.02%	532
2014 Q3	$619K	Buy	+62,498	New	+$925K	0.01%	800
2013 Q4	–	Sell	-8,741	Closed	-$234K	–	1627
2013 Q3	$234K	Buy	+8,741	New	+$187K	﹤0.01%	1128

Other funds holding RPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DCM

Destrier Capital Management New York $144M AUM 7.28% 1-Year Est. Return

Highbridge Capital Management's RPRX Position: Q3 2015 in Review

Highbridge Capital Management sold out of Repros Therapeutics Inc. (RPRX) in Q3 2015, closing a stake of 16,188 shares — an estimated $116K sold.

Highbridge Capital Management first reported a position in RPRX in Q3 2013 and held it in 5 quarters. The position peaked at $1.54M in Q4 2014. 58 funds tracked by Wall St. Rank hold RPRX as of Q3 2015.

Highbridge Capital Management reported no remaining Repros Therapeutics Inc. position as of Q3 2015 after selling out during the quarter.
Highbridge Capital Management sold 16,188 Repros Therapeutics Inc. shares in Q3 2015, an estimated $116K.
Highbridge Capital Management first reported a position in Repros Therapeutics Inc. in Q3 2013 and held it in 5 quarters.
Highbridge Capital Management's Repros Therapeutics Inc. position peaked at $1.54M in Q4 2014.
58 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q3 2015.

Based on Highbridge Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.